title: Anti-atherosclerotic effects of tamoxifen in cholesterol-fed ovariectomized rabbits.
abstract: It has been indicated that the anti-estrogen agent, tamoxifen, developed for the treatment of breast cancer, may act on the vascular system as an estrogen agonist. However, to our knowledge few reports suggest that tamoxifen exerts anti-atherogenic actions. In the present study, we evaluated the anti-atherosclerotic effects of tamoxifen in ovariectomized cholesterol-fed rabbits. Ovariectomized rabbits were fed a 1% cholesterol diet and divided into 4 groups: control group (C, n=5); estrogen treatment (E, n=6); low-dose tamoxifen treatment (0.5 mg/kg) (LT, n=6); and high-dose tamoxifen (1.0 mg/kg) (HT, n=7). After 6 weeks, both Oil red O-positive areas on the intimal surfaces of aortae and the ratios of intimal to medial areas (I/M ratios) measured from cross-sections of aortae were significantly lower in groups E, LT and HT compared with group C. Although there were no significant differences in serum NOx (NO2 and NO3) levels among the 4 groups, NOx levels were slightly higher in groups E, LT and HT than group C. Acetylcholine (ACh) was administered to all animals, and the responses of ear arteriole diameters were compared among the 4 groups. While ear arteriole diameters were significantly decreased in group C, no significant changes were observed in groups E, LT or HT following ACh administration. Ratios of ear arteriole diameters after to before ACh administration were significantly greater in groups E, LT and HT compared to group C. These findings suggest that tamoxifen exerts anti-atherosclerotic effects, and that these effects are attributed to the maintenance of vascular endothelial function.
authors.affiliation: Department of Pharmacology, and Intractable Disease Research Center, Tokyo Medical University, Japan.
authors.forename: Daishi
authors.initials: D
authors.lastname: Sugama
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nakajima
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Maehara
authors.forename: Ichie
authors.initials: I
authors.lastname: Hara
authors.forename: George F
authors.initials: GF
authors.lastname: Lawlor
authors.forename: Masato
authors.initials: M
authors.lastname: Inazu
authors.forename: Akira
authors.initials: A
authors.lastname: Yamashina
authors.forename: Teruhiko
authors.initials: T
authors.lastname: Matsumiya
mesh_terms: D000818:Animals; D001011:Aorta / Q000473:pathology; D001161:Arteriosclerosis / Q000503:physiopathology / Q000517:prevention & control*; D001774:Blood Chemical Analysis; D002791:Cholesterol, Dietary / Q000008:administration & dosage*; D008076:Cholesterol, HDL / Q000097:blood; D004730:Endothelium, Vascular / Q000503:physiopathology*; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D050356:Lipid Metabolism; D010052:Ovariectomy; D011817:Rabbits; D013629:Tamoxifen / Q000494:pharmacology*
chemical_list: D002791:Cholesterol, Dietary; D008076:Cholesterol, HDL; D004965:Estrogen Antagonists; D013629:Tamoxifen